You just read:

Stero Biotechs to Commence Phase 2 Clinical Trial of ST-AH-01 Cannabidiol Formulation for Ground Breaking Maintenance Therapy and Steroid Reduction in Patients With Autoimmune Hepatitis

News provided by

STERO Biotechs

Feb 28, 2019, 07:00 ET